Management of Suspected Encephalitis in Patients Receiving Daratumumab
In patients receiving daratumumab who develop suspected encephalitis, immediately initiate empiric acyclovir while pursuing urgent diagnostic workup (neuroimaging, CSF analysis, EEG), and strongly consider that daratumumab itself may be the causative agent requiring drug discontinuation and corticosteroid therapy.
Immediate Actions
Empiric Antiviral Therapy
- Start acyclovir immediately for all patients with suspected encephalitis, as HSV encephalitis is treatable and delay worsens outcomes 1
- Do not wait for diagnostic confirmation before initiating acyclovir
Urgent Diagnostic Evaluation
The diagnostic workup must include 1, 2:
- Neuroimaging: MRI is superior to CT for identifying CNS inflammation patterns; MRI may reveal specific localization suggesting particular etiologies
- CSF analysis: Look for pleocytosis (≥5 WBC/mm³), though absence does not exclude encephalitis, especially in immunocompromised patients receiving daratumumab
- EEG: May identify subclinical seizures or characteristic patterns (e.g., temporal lobe sharp waves in HSV)
- Serologic testing: Both CNS and systemic specimens
Critical Consideration: Daratumumab as Causative Agent
Drug-Induced Encephalopathy
Daratumumab can directly cause encephalopathy, though this is rare and not listed in standard FDA adverse event profiles 3. A documented case describes consciousness impairment after first daratumumab administration that resolved with prompt steroid therapy 4.
Key distinguishing features:
- Temporal relationship: Symptoms developing shortly after daratumumab administration
- Absence of infectious etiology on comprehensive workup
- Response to corticosteroids after drug discontinuation
Infection Risk from Immunosuppression
Daratumumab significantly increases infection risk 3:
- Grade 3-4 infections occur in 21-37% of patients in combination regimens
- Pneumonia is the most common severe infection
- Fatal infections (primarily pneumonia and sepsis) occur in 1-5% of patients
- Specific CNS infections reported: Cytomegalovirus, Listeriosis 3
- Herpes zoster reactivation occurs in 2-5% of patients
Treatment Algorithm
Step 1: Infectious vs. Autoimmune Differentiation
While awaiting diagnostic results:
- Continue acyclovir until HSV is excluded
- Assess for autoimmune features: Presence of autoantibodies (anti-NMDAR, anti-CASPR2, anti-GAD65) suggests autoimmune encephalitis 5, 6
- Consider daratumumab discontinuation if temporal relationship suggests drug causation
Step 2: Immunotherapy for Confirmed/Suspected Autoimmune Encephalitis
If infectious causes are excluded and autoimmune encephalitis is suspected 1:
First-line immunotherapy:
- High-dose methylprednisolone
- Plasma exchange or IVIG 1
Second-line for refractory cases:
- Rituximab (anti-CD20) for B-cell depletion
- Immunoadsorption
- Consider continuing or adding low-dose daratumumab paradoxically for plasma cell depletion in antibody-mediated disease 5, 6
Step 3: Refractory Disease Management
For patients failing standard immunotherapy 6, 7:
- Daratumumab may be therapeutic (not causative) in antibody-driven autoimmune encephalitis by depleting autoreactive plasma cells
- One case showed clinical improvement with daratumumab in anti-CASPR2 encephalitis after failure of steroids, plasma exchange, rituximab, and bortezomib 6
- However, this same patient died of Gram-negative sepsis, highlighting severe infection risk
Critical Pitfalls
Immunosuppression Complications
- Severe infection risk: Daratumumab causes profound immunosuppression with depletion of protective antibodies and altered T-cell function 6
- Monitor closely for bacterial sepsis, particularly Gram-negative organisms
- Consider prophylactic antimicrobials in heavily immunosuppressed patients
Laboratory Interference
Daratumumab binds CD38 on RBCs, interfering with blood bank testing 3:
- Treat reagent RBCs with DTT for compatibility testing
- In emergencies, transfuse non-cross-matched ABO/RhD-compatible RBCs
- This does not affect encephalitis management but is critical for concurrent care
Distinguishing Encephalitis from Encephalopathy
Encephalitis requires inflammatory CNS process, while encephalopathy (from metabolic, toxic, or systemic causes) does not 1. Daratumumab-associated consciousness impairment may represent encephalopathy rather than true encephalitis, affecting treatment approach.